TickerFacts.

Compare

Hypha Labs, Inc. vs 20/20 Biolabs, Inc. vs UL Solutions Inc.

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearHypha Labs, Inc.
FUNI		20/20 Biolabs, Inc.
AIDX		UL Solutions Inc.
ULS
Year ended2025-09-302025-12-312025-12-31
Revenuen/a$2.05M$3.05B
Revenue growth (YoY)n/a+16.7%+6.4%
Gross marginn/a29.6%49.5% (computed)
Operating marginn/a-162.9%17.1%
Net marginn/a-182.8%10.6%
Net income-$3.10M-$3.74M$325.00M
EPS (Diluted)-$0.02-$0.76$1.60
Operating cash flow-$380.0K-$1.92M$600.00M
Free cash flow-$412.9Kn/a$403.00M
Cash & equivalentsn/a$1.03M$295.00M
Total assets$409.2K$4.14M$2.92B
Total liabilities$2.51M$4.16M$1.63B
Shareholders' equity-$2.44M-$19.2K$1.29B
Return on year-end equityn/an/a25.1%
Shares outstanding147.12M5.44M201.03M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearHypha Labs, Inc.20/20 Biolabs, Inc.UL Solutions Inc.
Latest$2.70M
Ended 2022-09-30		$2.05M
Ended 2025-12-31		$3.05B
Ended 2025-12-31
1 year earlier$2.50M
Ended 2021-09-30		$1.75M
Ended 2024-12-31		$2.87B
Ended 2024-12-31
2 years earlier$2.57M
Ended 2020-09-30		n/a$2.68B
Ended 2023-12-31
3 years earlier$2.55M
Ended 2019-09-30		n/a$2.52B
Ended 2022-12-31
4 years earlier$2.84M
Ended 2018-09-30		n/an/a